Buy AOD9604 at Loti Labs

Molecular structure of AOD9604

AOD 9604 is a synthetic analogue derived from the C-terminal fragment of human growth hormone, specifically comprising the 16 amino acid sequence from residues 176-191 of the human growth hormone molecule.

Amino Sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe

Molecular Formula: C78H123N23O23S2

Molecular Weight: 1815.1 g/mol

CAS #: 221231-10-3

InChI: 1S/C78H123N23O23S2/c1-9-41…

The AOD 9604 peptide features a critical modification where the phenylalanine at the N-terminal end is replaced with tyrosine (Tyr), enhancing stability and bioavailability while preserving the lipolytic fragment properties essential for fat metabolism research.

Mechanism of action

The AOD 9604 peptide functions as an orally active peptide modelled on the fragment of human growth hormone responsible for fat burning properties. Unlike full-length growth hormone (hGH), this peptide specifically targets fat metabolism without stimulating insulin like growth factor (IGF-1) production or affecting growth hormone levels in ways that promote tissue growth.

Research demonstrates that AOD 9604 enhances lipolysis through beta-3 adrenergic receptor upregulation in adipose tissue. This mechanism triggers a signaling cascade involving increased cyclic AMP, which activates hormone-sensitive lipase to break down stored triglycerides into free fatty acids available for energy production. Studies suggest this pathway allows the body to burn fat more efficiently without the adverse effects associated with full human growth hormone therapy.

The peptide’s ability to reduce stubborn fat while preserving muscle mass stems from its selective action on adipose tissue. It demonstrates no impact on blood sugar or impaired glucose tolerance, distinguishing it from treatments that affect insulin resistance. This targeted approach makes AOD 9604 valuable for research into weight loss mechanisms and metabolic regulation.

Research Studies

Clinical trials have examined AOD 9604’s potential to treat obesity through multiple controlled investigations. A pivotal 12-week randomized study reported that subjects receiving AOD 9604 lost an average of 1.8 kg more than placebo controls, demonstrating statistically significant effects on fat loss.

A subsequent 24-week trial yielded less conclusive results, leading to discontinuation of development as an obesity treatment in 2007. However, this research established the peptide’s safety profile and confirmed its distinct mechanism from growth hormone therapies.

Studies in beta-3 adrenergic receptor knockout mice confirmed the pathway’s necessity for AOD 9604’s effects—animals lacking these receptors showed no lipolytic response, weight change, or fat oxidation benefits, validating the proposed mechanism of action.

Beyond weight loss applications, research has explored AOD 9604’s bone stimulating properties and potential applications in osteoporosis treatment. Additional investigations have examined its role in cartilage repair and joint health support through lipid mobilization mechanisms.

Storage and Safety

Proper storage ensures AOD 9604 peptide stability for research applications:

Lyophilized Form:

• Store at -20°C for long-term preservation
• Protect from light and moisture
• Stable for 24+ months under proper conditions

Reconstituted Form:

• Store at 2-8°C after reconstitution
• Use bacteriostatic water for reconstitution
• Consume within 4 weeks for optimal stability

Handle peptides in clean laboratory environments using sterile techniques. Avoid repeated freeze-thaw cycles that may degrade the amino acid structure and compromise research results.

Benefits of buying from Loti Labs

Loti Labs provides high-purity AOD 9604 manufactured under GMP conditions in USA facilities. Each batch undergoes rigorous third-party lab testing to verify purity and molecular integrity, ensuring reliable results for researchers investigating fat burning mechanisms and weight loss pathways.

Every order includes a certificate of analysis documenting purity verification results. Our quality control measures address the specific challenges of peptide manufacturing, including proper handling of the C-H bonds and molecular structures essential for biological activity.

Researchers studying how the body can burn fat and lose weight through peptide-mediated mechanisms require consistent, high-quality materials—Loti Labs delivers this standard for every AOD 9604 order.

Products from Loti Labs are for Research Use Only

All of the products sold by Loti Labs are intended as a research chemical only. This designation allows the use of this chemical strictly for in-vitro laboratory testing and experimentation. Human or veterinary use is strictly forbidden. This product is not a drug, food or cosmetic and may not be misbranded, mislabeled or misused as such.

AOD 9604 is provided exclusively for scientific investigation into fat metabolism, growth hormone pathways, and related biochemical research. It is not intended for any weight loss journey, peptide therapy, or efforts to build muscle in human applications.

Shipping Policy of Loti Labs

Loti Labs offers same day shipping for orders placed before 1pm EST Monday through Friday. Orders placed after 1pm EST or on weekends will be shipped the next business day.

Satisfaction Guarantee

Loti Labs offers a 30 day satisfaction guarantee on all products purchased from us. Simply return any unopened products to us for a full refund of the purchase price of the unused products.

Third Party Testing of Every Batch

Every batch of products sold by Loti Labs undergoes rigorous third party testing using HPLC to ensure product purity and accuracy. This verification process confirms the molecular structure and concentration meet research-grade standards.

References and citations

1. Ng FM, et al. “Metabolic effects of the C-terminal fragment of human growth hormone.” Endocrinology. Research on beta-3 adrenergic receptor mechanisms.
2. Metabolic Pharmaceuticals clinical trial data on AOD 9604 lipolytic effects in human subjects.
3. Studies on Tyr-hGH177-191 prepared via solid-phase peptide synthesis for safety and tolerability evaluation.
4. Journal of Endocrinology (2008). Research confirming lipid oxidation increases without GH or IGF-1 signaling activation.
5. PubChem compound database entries for AOD 9604 molecular specifications.
6. Beta-3 adrenergic receptor knockout studies validating mechanism of action in animal models.